Microbiota, co-metabolites, and network pharmacology reveal the alteration of the ginsenoside fraction on inflammatory bowel disease.

Publication Year: 2022

DOI:
10.1016/j.jgr.2022.04.001

PMCID:
PMC9834002

PMID:
36644384

Journal Information

Full Title: J Ginseng Res

Abbreviation: J Ginseng Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Integrative & Complementary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of competing interest The authors declare no conflict of interest."

Evidence found in paper:

"Funding This work was supported by the 10.13039/501100012166National Key Research and Development Program of China [2017YFC1702100], the 10.13039/501100001809National Natural Science Foundation of China [81603276, U19A2013 and 82004099], the 10.13039/501100011789Department of Science and Technology of Jilin Province [20190101010JH, 20200201419JC and 202002053JC], and the Science and Technology Projects in Jilin Province Department of Education [JJKH20200903KJ]. Key Laboratory of Active Substances and Biological Mechanisms of Ginseng Efficacy, Ministry of Education. Jilin Provincial Key Laboratory of Bio-Macromolecules of Chinese Medicine."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025